Moderna (MRNA) Ascends While Market Falls: Some Facts to Note

Moderna (MRNA) closed at $146.69, up 1.89%, outperforming the S&P 500 despite rising 127.37% in the past month. However, the company faces headwinds with expected EPS of -$1.36 (down 166.67% YoY) and revenue projected at $888.78 million (down 12.52% YoY). The stock holds a Zacks Rank #3 (Hold) rating with a modest 1.42% increase in consensus EPS estimates over 30 days.